Pharmaceutical Last week saw the US Food and Drug Administration’s vaccines advisory committee deliberate on the approval process for vaccines against COVID-19. Among research news, US biotech Aptinyx scored a hit with investors when it presented Phase II results with its post-traumatic stress syndrome candidate NYX-783. Along with its third-quarter financials, Biogen updated on progress with its Alzheimer’s candidate aducanumab. Gilead Sciences gained full approval from the US FDA for its coronavirus treatment Veklury. 25 October 2020